相关实验视频

Updated: Sep 20, 2025

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

在阿尔茨海默氏病的小鼠模型中,塔克罗利减轻了病态模式

Giovanni Freitas Gomes¹, Carla Ribeiro Álvares Batista¹, Maria Carolina Machado da Silva¹

¹Neuropharmacology Laboratory, Department of Pharmacology, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

|May 24, 2025

概括

塔克罗利斯 (FK506) 在阿尔茨海默氏症 (AD) 模型中显示出神经保护作用. 它在一些模型中减轻了认知缺陷和神经毒性,为AD治疗提供了潜力.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.

背景情况:

阿尔茨海默氏病 (AD) 的特征是神经炎症和破坏的谷氨酸性神经传递.
塔克罗利 (FK506) 是一种氨尿素抑制剂 (CNI),目前正在研究AD治疗潜力.
它在AD模型中的确切影响和机制需要进一步研究.

研究的目的:

为了研究TACROLIMUS在AD模型中的神经保护作用.
评估其对认知缺陷,神经毒性和微质症的影响.
评估其对谷氨酸释放失调的影响.

主要方法:

使用Aβ1-42诱导的海马内损伤和中年转基因APP/PS1小鼠模型.
使用单剂量和30天的塔克罗利斯治疗.
评估认知功能 (NORT,社会互动),神经退行,微质症和突触体中谷氨酸酸释放.

主要成果:

一次性塔克罗利斯剂量预防了Aβ1-42诱导的认知障碍,并减少了神经退行.
在APP/PS1小鼠中,慢性治疗并没有预防记忆障碍,但改善了社交互动和减少了微质症.
在APP/PS1小鼠中,塔克罗利马斯恢复了内突触体内水平,并使谷氨酸释放正常化.

结论:

在AD模型中,塔克罗利木斯表现出神经保护作用,无论是急性还是慢性.
这些发现支持塔克罗利斯在治疗阿尔茨海默病的潜在治疗应用.
对阿尔茨海默病的氨酸抑制剂进行进一步的研究是有必要的.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.氨酸是氨酸中的一种.在FK506中使用.谷氨酸酸盐的使用方法微结质症是一种微结质症.神经退行发生神经退行.

更多相关视频

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Published on: May 3, 2017

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...